Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q96LA8

UPID:
ANM6_HUMAN

ALTERNATIVE NAMES:
Heterogeneous nuclear ribonucleoprotein methyltransferase-like protein 6; Histone-arginine N-methyltransferase PRMT6

ALTERNATIVE UPACC:
Q96LA8; A3KME1; B4DID8; Q5T5Y5; Q6DKI4; Q9NVR8

BACKGROUND:
The enzyme Protein arginine N-methyltransferase 6, also known as PRMT6, catalyzes the formation of omega-N monomethylarginine and asymmetrical dimethylarginine. It preferentially methylates arginyl residues in specific domains, playing a crucial role in epigenetic transcriptional repression and DNA repair by mediating the methylation of various proteins, including histones and DNA polymerase beta.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Protein arginine N-methyltransferase 6 offers a promising pathway to novel therapeutic interventions. Given its significant role in epigenetic regulation and DNA repair, targeting PRMT6 could provide innovative treatments for conditions associated with epigenetic alterations and impaired DNA repair mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.